Acutaas Chemicals Ltd (NSE: ACUTAAS, BSE: 543349) is a Surat, Gujarat-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹26,248 Cr, it ranks #313 by market cap among the 6,137 Indian listed companies on FinBizNet, and #15 of 86 in Medicinal Chemicals and Botanical Products. At ₹3,137.70 (as of 25 Oct 2026), the share price is 16.1% below its 52-week high of ₹3,740.00 and 99.9% above its 52-week low of ₹1,570.00. The share price is up 102.0% over one year and down 3.7% over three months.
| Current Price | ₹3,137.70 |
|---|---|
| Market Cap | ₹26,248 Cr |
| NSE Symbol | ACUTAAS |
| BSE Code | 543349 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 75.2 |
| Return on Equity | 23.52% |
| Return on Assets | 15.74% |
| 52-Week Range | ₹1,570.00 – ₹3,740.00 |
| 1-Year Price Change | +102.0% |
| 3-Month Price Change | -3.7% |
| Beta (1Y) | 0.28 |
| Dividend Yield | 0.08% |
| Headquarters | Surat, Gujarat |
| Website | www.acutaas.com |
| Revenue | ₹330 Cr |
|---|---|
| Net Profit | ₹75 Cr |
| Net Margin | 22.7% |
| EPS (Basic) | ₹9.07 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson’s, antidepressant, and anticoagulant applications. It also provides specialty chemicals for use in battery chemicals, personal care, agrochemicals, coatings, electronics, and industrial processes; photoresist chemicals to semiconductor applications; electrolyte additives for lithium battery cells; and parabens, methyl salicylate, and other commodity chemicals for cosmetics, agrochemicals, and fine chemicals. The company was formerly known as Ami Organics Limited and changed its name to Acutaas Chemicals Limited in May 2025. Acutaas Chemicals Limited was founded in 2004 and is based in Surat, India.
1. Custom Synthesis and Manufacturing of Speciality Chemicals-This segment engages in manufacturing pharmaceutical intermediates for active pharmaceutical ingredients. 2. NA-NA 3. NA-NA 4. NA-NA
1. Specialty Chemicals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Acutaas Chemicals Ltd | ₹26,248 Cr | 75.2 | 23.52% | ₹330 Cr | +102.0% |
Listed by market capitalisation. Ratios are shown for context only.
Acutaas Chemicals Ltd is trading at ₹3,137.70, with a market capitalisation of ₹26,248 Cr.
Acutaas Chemicals Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Acutaas Chemicals Ltd has a P/E of 75.2 and a return on equity of 23.52%.
Acutaas Chemicals Ltd is listed on the NSE under the symbol ACUTAAS and on the BSE under the scrip code 543349.
Acutaas Chemicals Ltd's share price is up 102.0% over one year and down 3.7% over three months. Its 52-week range is ₹1,570.00 to ₹3,740.00.
In Q1 FY27, Acutaas Chemicals Ltd reported revenue of ₹330 Cr and net profit of ₹75 Cr, with basic EPS of ₹9.07 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.